These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 34338636)

  • 1. Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes.
    Grafton F; Ho J; Ranjbarvaziri S; Farshidfar F; Budan A; Steltzer S; Maddah M; Loewke KE; Green K; Patel S; Hoey T; Mandegar MA
    Elife; 2021 Aug; 10():. PubMed ID: 34338636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes.
    Kopljar I; De Bondt A; Vinken P; Teisman A; Damiano B; Goeminne N; Van den Wyngaert I; Gallacher DJ; Lu HR
    Br J Pharmacol; 2017 Nov; 174(21):3766-3779. PubMed ID: 28094846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.
    Zwartsen A; de Korte T; Nacken P; de Lange DW; Westerink RHS; Hondebrink L
    J Mol Cell Cardiol; 2019 Nov; 136():102-112. PubMed ID: 31526813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying drug-induced structural toxicity in hepatocytes and cardiomyocytes derived from hiPSCs using a deep learning method.
    Maddah M; Mandegar MA; Dame K; Grafton F; Loewke K; Ribeiro AJS
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106895. PubMed ID: 32629158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human-Induced Pluripotent Stem Cell-Based Differentiation of Cardiomyocyte Subtypes for Drug Discovery and Cell Therapy.
    Pan Z; Liang P
    Handb Exp Pharmacol; 2023; 281():209-233. PubMed ID: 37421443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of hERG1a and hERG1b isoforms on drug safety screening in iPSC-CMs.
    Goversen B; Jonsson MK; van den Heuvel NH; Rijken R; Vos MA; van Veen TA; de Boer TP
    Prog Biophys Mol Biol; 2019 Dec; 149():86-98. PubMed ID: 30826123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-based toxicity screening in human induced pluripotent stem cell-derived cardiomyocytes.
    Burnett SD; Blanchette AD; Grimm FA; House JS; Reif DM; Wright FA; Chiu WA; Rusyn I
    Toxicol Appl Pharmacol; 2019 Oct; 381():114711. PubMed ID: 31425687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems.
    Magdy T; Schuldt AJT; Wu JC; Bernstein D; Burridge PW
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():83-103. PubMed ID: 28992430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening.
    Ovics P; Regev D; Baskin P; Davidor M; Shemer Y; Neeman S; Ben-Haim Y; Binah O
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023024
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity.
    Sharma A; McKeithan WL; Serrano R; Kitani T; Burridge PW; Del Álamo JC; Mercola M; Wu JC
    Nat Protoc; 2018 Dec; 13(12):3018-3041. PubMed ID: 30413796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of in vitro models of stem cell-derived cardiomyocytes to screen for potential cardiotoxicity of chemicals.
    Shi M; Tien NT; de Haan L; Louisse J; Rietjens IMCM; Bouwmeester H
    Toxicol In Vitro; 2020 Sep; 67():104891. PubMed ID: 32446838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity.
    Sirenko O; Cromwell EF; Crittenden C; Wignall JA; Wright FA; Rusyn I
    Toxicol Appl Pharmacol; 2013 Dec; 273(3):500-7. PubMed ID: 24095675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs-a proof-of-concept study with doxorubicin.
    Pang L; Cai C; Aggarwal P; Wang D; Vijay V; Bagam P; Blamer J; Matter A; Turner A; Ren L; Papineau K; Srinivasasainagendra V; Tiwari HK; Yang X; Schnackenberg L; Mattes W; Broeckel U
    Toxicol Sci; 2024 Jun; 200(1):79-94. PubMed ID: 38547396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of KCNJ2 enhances maturation of human-induced pluripotent stem cell-derived cardiomyocytes.
    Zhou J; Cui B; Wang X; Wang H; Zheng J; Guo F; Sun Y; Fan H; Shen J; Su J; Wang J; Zhao H; Tang Y; Gong T; Sun N; Liang P
    Stem Cell Res Ther; 2023 Apr; 14(1):92. PubMed ID: 37061738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Batch Variations in Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes from 2 Major Suppliers.
    Huo J; Kamalakar A; Yang X; Word B; Stockbridge N; Lyn-Cook B; Pang L
    Toxicol Sci; 2017 Mar; 156(1):25-38. PubMed ID: 28031415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manipulation-free cultures of human iPSC-derived cardiomyocytes offer a novel screening method for cardiotoxicity.
    Rajasingh S; Isai DG; Samanta S; Zhou ZG; Dawn B; Kinsey WH; Czirok A; Rajasingh J
    Acta Pharmacol Sin; 2018 Oct; 39(10):1590-1603. PubMed ID: 29620051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
    Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
    Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
    Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
    Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Machine-learning-based quality control of contractility of cultured human-induced pluripotent stem-cell-derived cardiomyocytes.
    Orita K; Sawada K; Matsumoto N; Ikegaya Y
    Biochem Biophys Res Commun; 2020 Jun; 526(3):751-755. PubMed ID: 32265031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.